152 related articles for article (PubMed ID: 30967849)
21. Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScope® and the literature.
Seidel D; Hassler A; Salmanton-García J; Koehler P; Mellinghoff SC; Carlesse F; Cheng MP; Falces-Romero I; Herbrecht R; Jover Sáenz A; Klimko N; Mareş M; Lass-Flörl C; Soler-Palacín P; Wisplinghoff H; Cornely OA; Pana Z; Lehrnbecher T
Int J Infect Dis; 2020 Mar; 92():114-122. PubMed ID: 31863876
[TBL] [Abstract][Full Text] [Related]
22. In vitro characterization of anti-glucosylceramide rabbit antisera.
Brade L; Vielhaber G; Heinz E; Brade H
Glycobiology; 2000 Jun; 10(6):629-36. PubMed ID: 10814705
[TBL] [Abstract][Full Text] [Related]
23. Cyclophilin and enolase are the most prevalent conidial antigens of Lomentospora prolificans recognized by healthy human salivary IgA and cross-react with Aspergillus fumigatus.
Buldain I; Ramirez-Garcia A; Pellon A; Antoran A; Sevilla MJ; Rementeria A; Hernando FL
Proteomics Clin Appl; 2016 Oct; 10(9-10):1058-1067. PubMed ID: 27485921
[TBL] [Abstract][Full Text] [Related]
24. Disseminated
Nasif A; Siebenaller D; DeRiso A; Shah H; Alharthi S; Nazzal M
J Vasc Surg Cases Innov Tech; 2021 Dec; 7(4):785-789. PubMed ID: 34849438
[No Abstract] [Full Text] [Related]
25. Quality control of fungus-specific glucosylceramide in Cryptococcus neoformans by endoglycoceramidase-related protein 1 (EGCrP1).
Ishibashi Y; Ikeda K; Sakaguchi K; Okino N; Taguchi R; Ito M
J Biol Chem; 2012 Jan; 287(1):368-381. PubMed ID: 22072709
[TBL] [Abstract][Full Text] [Related]
26. Investigation of a
Boan P; Pang S; Gardam DJ; Darragh H; Wright M; Coombs GW
Med Mycol Case Rep; 2020 Sep; 29():1-4. PubMed ID: 32477857
[No Abstract] [Full Text] [Related]
27. Pathobiology of Lomentospora prolificans: could this species serve as a model of primary antifungal resistance?
Pellon A; Ramirez-Garcia A; Buldain I; Antoran A; Martin-Souto L; Rementeria A; Hernando FL
Int J Antimicrob Agents; 2018 Jan; 51(1):10-15. PubMed ID: 28669833
[TBL] [Abstract][Full Text] [Related]
28. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.
Wiederhold NP; Law D; Birch M
J Antimicrob Chemother; 2017 Jul; 72(7):1977-1980. PubMed ID: 28333310
[TBL] [Abstract][Full Text] [Related]
29. Molecular and cellular responses of the pathogenic fungus Lomentospora prolificans to the antifungal drug voriconazole.
Pellon A; Ramirez-Garcia A; Buldain I; Antoran A; Rementeria A; Hernando FL
PLoS One; 2017; 12(3):e0174885. PubMed ID: 28362854
[TBL] [Abstract][Full Text] [Related]
30. Targeted Disruption of Melanin Biosynthesis Genes in the Human Pathogenic Fungus Lomentospora prolificans and Its Consequences for Pathogen Survival.
Al-Laaeiby A; Kershaw MJ; Penn TJ; Thornton CR
Int J Mol Sci; 2016 Mar; 17(4):444. PubMed ID: 27023523
[TBL] [Abstract][Full Text] [Related]
31. Effects of UVC Irradiation on Growth and Apoptosis of
Muangkaew W; Suwanmanee S; Singkum P; Pumeesat P; Luplertlop N
Interdiscip Perspect Infect Dis; 2018; 2018():3748594. PubMed ID: 30631350
[No Abstract] [Full Text] [Related]
32. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope
Seidel D; Meißner A; Lackner M; Piepenbrock E; Salmanton-García J; Stecher M; Mellinghoff S; Hamprecht A; Durán Graeff L; Köhler P; Cheng MP; Denis J; Chedotal I; Chander J; Pakstis DL; Los-Arcos I; Slavin M; Montagna MT; Caggiano G; Mares M; Trauth J; Aurbach U; Vehreschild MJGT; Vehreschild JJ; Duarte RF; Herbrecht R; Wisplinghoff H; Cornely OA
Crit Rev Microbiol; 2019 Feb; 45(1):1-21. PubMed ID: 30628529
[TBL] [Abstract][Full Text] [Related]
33. Lomentospora prolificans endocarditis--case report and literature review.
Kelly M; Stevens R; Konecny P
BMC Infect Dis; 2016 Jan; 16():36. PubMed ID: 26822980
[TBL] [Abstract][Full Text] [Related]
34.
Wangchinda W; Chongtrakool P; Tanboon J; Jitmuang A
Med Mycol Case Rep; 2018 Sep; 21():26-29. PubMed ID: 30073138
[No Abstract] [Full Text] [Related]
35. Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.
Mor V; Farnoud AM; Singh A; Rella A; Tanno H; Ishii K; Kawakami K; Sato T; Del Poeta M
PLoS One; 2016; 11(4):e0153853. PubMed ID: 27082428
[TBL] [Abstract][Full Text] [Related]
36. Eradication of
Lee J; Wilson M; Casey N
Case Rep Orthop; 2020; 2020():8271471. PubMed ID: 33014492
[No Abstract] [Full Text] [Related]
37. Human phagocytic cell responses to Scedosporium prolificans.
Gil-Lamaignere C; Maloukou A; Rodriguez-Tudela JL; Roilides E
Med Mycol; 2001 Apr; 39(2):169-75. PubMed ID: 11346264
[TBL] [Abstract][Full Text] [Related]
38. Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials.
Nimrichter L; Rodrigues ML
Front Microbiol; 2011; 2():212. PubMed ID: 22025918
[TBL] [Abstract][Full Text] [Related]
39. O-glycosylation in cell wall proteins in Scedosporium prolificans is critical for phagocytosis and inflammatory cytokines production by macrophages.
Xisto MI; Bittencourt VC; Liporagi-Lopes LC; Haido RM; Mendonça MS; Sassaki G; Figueiredo RT; Romanos MT; Barreto-Bergter E
PLoS One; 2015; 10(4):e0123189. PubMed ID: 25875427
[TBL] [Abstract][Full Text] [Related]
40. Comparative Pathogenicity of Lomentospora prolificans (Scedosporium prolificans) Isolates from Mexican Patients.
Elizondo-Zertuche M; Montoya AM; Robledo-Leal E; Garza-Veloz I; Sánchez-Núñez AL; Ballesteros-Elizondo R; González GM
Mycopathologia; 2017 Aug; 182(7-8):681-689. PubMed ID: 28456868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
